Basilard BioTech
Basilard BioTech is a Southern-California-based company leading innovation in cell and gene therapy engineering with its proprietary Celletto™ platform. The company aims to revolutionize gene delivery methods by providing a disruptive, nanomechanical approach that overcomes limitations of current viral and non-viral techniques, enabling scalable, safe, and cost-effective cell-based therapies.
Industries
Nr. of Employees
small (1-50)
Products
Nanomechanical gene delivery platform (prototype device)
Microfluidic/MEMS-based device that generates a single transient pore per cell via fluid-driven positioning on nanoscale structures to enable high-efficiency intracellular and intranuclear delivery with preserved cell viability.
Nanomechanical gene delivery platform (prototype device)
Microfluidic/MEMS-based device that generates a single transient pore per cell via fluid-driven positioning on nanoscale structures to enable high-efficiency intracellular and intranuclear delivery with preserved cell viability.
Services
Fabrication and delivery of microfluidic/MEMS prototype chips and devices for evaluation and validation.
Validation testing of devices internally and in partnership with external research institutions and potential co-development partners to assess transfection performance and viability.
Collaborative co-development arrangements with cell and gene therapy companies to integrate and evaluate the gene delivery platform within therapeutic development pipelines.
Advisory services leveraging in-house and advisor expertise in MEMS, microfluidics, process development, and cell therapy manufacturing for technology integration and scale-up planning.
Fabrication and delivery of microfluidic/MEMS prototype chips and devices for evaluation and validation.
Validation testing of devices internally and in partnership with external research institutions and potential co-development partners to assess transfection performance and viability.
Collaborative co-development arrangements with cell and gene therapy companies to integrate and evaluate the gene delivery platform within therapeutic development pipelines.
Advisory services leveraging in-house and advisor expertise in MEMS, microfluidics, process development, and cell therapy manufacturing for technology integration and scale-up planning.
Expertise Areas
- Non-viral gene delivery
- Ex vivo cell therapy engineering
- Microfluidics and MEMS device development
- Prototype chip fabrication and scale-up
Key Technologies
- Deterministic mechanoporation (DMP)
- Nanoneedle / nanoneedle arrays
- Microfluidics
- MEMS and semiconductor fabrication
News & Updates
Analysis of how four nanomedicine start-ups overcame the biotech valley of death and built timely success.
Interview discussing the combination of microfluidics and MEMS silicon technology in biotechnology.
Announcement of Basilard BioTech's revolutionary nanomechanical gene delivery platform, SoloPore™, and its potential to improve ex vivo cell and gene therapy engineering.
Research publication detailing the high efficiency and uniformity of Basilard's Celletto™ platform in transfecting primary human T cells.
Analysis of how four nanomedicine start-ups overcame the biotech valley of death and built timely success.
Interview discussing the combination of microfluidics and MEMS silicon technology in biotechnology.
Announcement of Basilard BioTech's revolutionary nanomechanical gene delivery platform, SoloPore™, and its potential to improve ex vivo cell and gene therapy engineering.
Research publication detailing the high efficiency and uniformity of Basilard's Celletto™ platform in transfecting primary human T cells.